MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Legend Biotech Corp ADR

Gesloten

SectorGezondheidszorg

33.29 5.75

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.96

Max

33.51

Belangrijke statistieken

By Trading Economics

Inkomsten

161M

41M

Verkoop

26M

187M

EPS

0.14

Winstmarge

21.719

Werknemers

2,600

EBITDA

162M

52M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+164.47% upside

Dividenden

By Dow Jones

Volgende Winsten

12 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-30M

6.4B

Vorige openingsprijs

27.54

Vorige sluitingsprijs

33.29

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Legend Biotech Corp ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 mei 2024, 11:36 UTC

Winsten

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 mrt 2025, 11:09 UTC

Winsten

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mrt 2025, 11:08 UTC

Winsten

Legend Biotech 4Q EPS 7c >LEGN

11 mrt 2025, 11:00 UTC

Winsten

Legend Biotech 4Q Rev $186.5M >LEGN

12 nov 2024, 12:06 UTC

Winsten

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 nov 2024, 12:05 UTC

Winsten

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 nov 2024, 12:00 UTC

Winsten

Legend Biotech 3Q Rev $160.2M >LEGN

9 aug 2024, 11:02 UTC

Winsten

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 aug 2024, 11:01 UTC

Winsten

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 aug 2024, 11:01 UTC

Winsten

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 aug 2024, 11:00 UTC

Winsten

Legend Biotech 2Q Rev $186.5M >LEGN

26 jul 2024, 11:01 UTC

Winsten

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 mei 2024, 11:02 UTC

Winsten

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 mei 2024, 11:02 UTC

Winsten

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Peer Vergelijking

Prijswijziging

Legend Biotech Corp ADR Prognose

Koersdoel

By TipRanks

164.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 83.36 USD  164.47%

Hoogste 95 USD

Laagste 62 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Legend Biotech Corp ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

13

Buy

2

Hold

0

Sell

Technische score

By Trading Central

31.39 / 35.05Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.